Fred Okuku1, Elizabeth M Krantz, James Kafeero, Moses R Kamya, Jackson Orem, Corey Casper, Warren Phipps. 1. *Uganda Cancer Institute, Kampala, Uganda; †Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda; ‡Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Departments of §Medicine; ‖Epidemiology; and ¶Global Health, University of Washington, Seattle, WA.
Abstract
BACKGROUND: HIV-associated Kaposi sarcoma (KS) is commonly staged using the AIDS Clinical Trials Group criteria, which classify 3 variables- tumor extent (T), immune status (I), and systemic symptoms (S)-into good risk (0) and poor risk (1). Although validated in the United States and Europe, these criteria have not been systematically evaluated in sub-Saharan Africa, where the burden of KS is greatest. METHODS: We reviewed medical charts of adult patients with HIV-associated KS seen at the Uganda Cancer Institute from 1992 to 2007. Vital status at 2 years after KS diagnosis was determined from the medical chart, or by contacting the patient or next of kin. Survival estimates used Kaplan-Meier methods. Predictors were evaluated for 2 periods: 0-4 months and 4-24 months after diagnosis. RESULTS: At 2 years after diagnosis, 167 (41%) patients were alive, 156 (39%) had died, and 81 (20%) were lost to follow-up. The Kaplan-Meier estimate of 2-year survival was 57%. S1 was associated with death in months 0-4 [hazard ratio: 6.4, 95% confidence interval: 1.9-21.1], whereas T1 was associated with death in months 4-24 [hazard ratio: 4.0, 95% confidence interval: 1.4 to 11.5]. Immune status was not associated with survival. CONCLUSIONS: Systemic symptoms were strongly associated with death in the early period after KS diagnosis, whereas tumor status was most predictive of death in the 4- to 24-month period. These findings suggest that different processes may influence outcomes in early and late periods following KS diagnosis. Further studies are needed to confirm these observations and to identify better predictors of KS survival in sub-Saharan Africa.
BACKGROUND:HIV-associated Kaposi sarcoma (KS) is commonly staged using the AIDS Clinical Trials Group criteria, which classify 3 variables- tumor extent (T), immune status (I), and systemic symptoms (S)-into good risk (0) and poor risk (1). Although validated in the United States and Europe, these criteria have not been systematically evaluated in sub-Saharan Africa, where the burden of KS is greatest. METHODS: We reviewed medical charts of adult patients with HIV-associated KS seen at the Uganda Cancer Institute from 1992 to 2007. Vital status at 2 years after KS diagnosis was determined from the medical chart, or by contacting the patient or next of kin. Survival estimates used Kaplan-Meier methods. Predictors were evaluated for 2 periods: 0-4 months and 4-24 months after diagnosis. RESULTS: At 2 years after diagnosis, 167 (41%) patients were alive, 156 (39%) had died, and 81 (20%) were lost to follow-up. The Kaplan-Meier estimate of 2-year survival was 57%. S1 was associated with death in months 0-4 [hazard ratio: 6.4, 95% confidence interval: 1.9-21.1], whereas T1 was associated with death in months 4-24 [hazard ratio: 4.0, 95% confidence interval: 1.4 to 11.5]. Immune status was not associated with survival. CONCLUSIONS: Systemic symptoms were strongly associated with death in the early period after KS diagnosis, whereas tumor status was most predictive of death in the 4- to 24-month period. These findings suggest that different processes may influence outcomes in early and late periods following KS diagnosis. Further studies are needed to confirm these observations and to identify better predictors of KS survival in sub-Saharan Africa.
Authors: G Nasti; D Serraino; A Ridolfo; A Antinori; G Rizzardini; C Zeroli; L Nigro; M Tavio; E Vaccher; U Tirelli Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-04-01
Authors: Justin Stebbing; Adam Sanitt; Alastair Teague; Tom Powles; Mark Nelson; Brian Gazzard; Mark Bower Journal: J Clin Oncol Date: 2007-04-30 Impact factor: 44.544
Authors: Emmanuelle Boffi El Amari; Laurence Toutous-Trellu; Angèle Gayet-Ageron; Michele Baumann; Gieri Cathomas; Ingrid Steffen; Peter Erb; Nicolas J Mueller; Hansjakob Furrer; Matthias Cavassini; Pietro Vernazza; Hans H Hirsch; Enos Bernasconi; Bernard Hirschel Journal: AIDS Date: 2008-05-31 Impact factor: 4.177
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Mina C Hosseinipour; Minhee Kang; Susan E Krown; Aggrey Bukuru; Triin Umbleja; Jeffrey N Martin; Jackson Orem; Catherine Godfrey; Brenda Hoagland; Noluthando Mwelase; Deborah Langat; Mulinda Nyirenda; John MacRae; Margaret Borok; Wadzanai Samaneka; Agnes Moses; Rosie Mngqbisa; Naftali Busakhala; Otoniel Martínez-Maza; Richard Ambinder; Dirk P Dittmer; Mostafa Nokta; Thomas B Campbell Journal: Clin Infect Dis Date: 2018-07-02 Impact factor: 9.079
Authors: Esther E Freeman; Aggrey Semeere; Devon E McMahon; Helen Byakwaga; Miriam Laker-Oketta; Susan Regan; Megan Wenger; Charles Kasozi; Matthew Ssemakadde; Mwebesa Bwana; Michael Kanyesigye; Philippa Kadama-Makanga; Elyne Rotich; Job Kisuya; Kara Wools-Kaloustian; Ingrid V Bassett; Naftali Busakhala; Jeffrey Martin Journal: J Acquir Immune Defic Syndr Date: 2021-08-15 Impact factor: 3.771
Authors: Naftali Busakhala; Gabriel Kigen; Paul Waako; R Matthew Strother; Fredrick Chite; Patrick Loehrer Journal: Infect Agent Cancer Date: 2019-09-10 Impact factor: 2.965
Authors: Katherine R Sabourin; Margaret Borok; Samantha Mawhinney; Maxwell Matimba; Francis Jaji; Suzanne Fiorillo; Dickson D Chifamba; Claudios Muserere; Busisiwe Mashiri; Chenjerai Bhodheni; Patricia Gambiza; Rachael Mandidewa; Mercia Mutimuri; Ivy Gudza; Matthew Mulvahill; Camille M Moore; Jean S Kutner; Eric A F Simões; Thomas B Campbell Journal: J Int AIDS Soc Date: 2022-08 Impact factor: 6.707